Cochrane · systematic review · CD011281
Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis
Andrade‐Castellanos, CA, Colunga‐Lozano, LE, Delgado‐Figueroa, N, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
Metabolic and Endocrine DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
8
No studies
5
Included studies
NR
No studies 5 · 35.7%Ungraded 1 · 7.1%Very low 2 · 14.3%Low 5 · 35.7%Moderate 1 · 7.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Subcutaneous insulin lispro versus intravenous regular insulin for diabetic ketoacidosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality (N) Mean hospital stay: 2‐7 days Subcutaneous insulin lispro vs intravenous regular insulin | no estimate extracted | 4 studies · 156 participants | Moderate Downgraded: imprecision |
Hypoglycaemic episodes (N) Mean hospital stay: 2‐7 days Subcutaneous insulin lispro vs intravenous regular insulin | RR 0.59 [0.23, 1.52] | 4 studies · 156 participants | Low Downgraded: risk of bias, imprecision |
Morbidity (N) Mean hospital stay: 2‐7 days Subcutaneous insulin lispro vs intravenous regular insulin | no estimate extracted | 2 studies · 96 participants | Ungraded |
Adverse events other than hypoglycaemic episodes Subcutaneous insulin lispro vs intravenous regular insulin | no estimate extracted | NR | No studies |
Time to resolution of diabetic ketoacidosis (h) Mean hospital stay: 2‐4 days Subcutaneous insulin lispro vs intravenous regular insulin | no estimate extracted | 2 studies · 90 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Patient satisfaction Subcutaneous insulin lispro vs intravenous regular insulin | no estimate extracted | NR | No studies |
Socioeconomic effects: length of hospital stay (days) Mean hospital stay: 4‐7 days Subcutaneous insulin lispro vs intravenous regular insulin | no estimate extracted | 2 studies · 90 participants | Low Downgraded: imprecision |
Subcutaneous insulin aspart versus intravenous regular insulin for diabetic ketoacidosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality (N) Mean hospital stay: 3‐5 days Subcutaneous insulin aspart vs intravenous regular insulin | no estimate extracted | 1 study · 45 participants | Low Downgraded: imprecision |
Hypoglycaemic episodes (N) Mean hospital stay: 3‐5 days Subcutaneous insulin aspart vs intravenous regular insulin | RR 1 [0.07, 14.55] | 1 study · 30 participants | Low Downgraded: risk of bias, imprecision |
Morbidity Subcutaneous insulin aspart vs intravenous regular insulin | no estimate extracted | NR | No studies |
Adverse events other than hypoglycaemic episodes Subcutaneous insulin aspart vs intravenous regular insulin | no estimate extracted | NR | No studies |
Time to resolution of diabetic ketoacidosis (h) Mean hospital stay: 3‐5 days Subcutaneous insulin aspart vs intravenous regular insulin | no estimate extracted | 1 study · 30 participants | Very low Downgraded: risk of bias, imprecision |
Patient satisfaction Subcutaneous insulin aspart vs intravenous regular insulin | no estimate extracted | NR | No studies |
Socioeconomic effects: length of hospital stay (days) Mean hospital stay: 3‐5 days Subcutaneous insulin aspart vs intravenous regular insulin | no estimate extracted | 1 study · 30 participants | Low Downgraded: imprecision |